Argenx (ARGX) said Friday that Japan's Ministry of Health, Labour and Welfare approved its Vyvdura injection as a treatment for adult patients with chronic inflammatory demyelinating polyneuropathy, a progressive and debilitating neuromuscular disorder of the peripheral nervous system.
The approval is based on the results of a study, which showed that 69% of patients treated with the drug demonstrated clinical improvements, including in mobility, function and strength.
The Japanese regulator approved Vyvdura for manufacturing and marketing in January. The drug was launched in April for the treatment of generalized myasthenia gravis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。